Could atomoxetine or metformin be the next Alzheimer's treatment?

NCT ID NCT07724132

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether two existing drugs—atomoxetine, typically used for ADHD, and metformin, a diabetes medication—can slow cognitive and functional decline in people with Alzheimer's disease. Around 1,200 participants aged 55 and older with mild to moderate Alzheimer's will receive one of the drugs or a placebo for 18 months. Researchers will measure changes in memory, thinking skills, and daily living abilities to see if either drug offers a benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
atomoxetine and metformin, two existing drugs repurposed for Alzheimer's disease
What this could lead to
If successful, this could point toward new, readily available treatments to slow cognitive decline in Alzheimer's disease.
What could go wrong
These are repurposed drugs not originally designed for Alzheimer's, and the trial is still testing whether they work at all. Side effects from atomoxetine or metformin may limit tolerability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Two Bridges Research & Development Clinic

    RECRUITING

    Chertsey, KT16 9AU, United Kingdom

  • Windsor Research Unit

    RECRUITING

    Cambridge, CB21 5EF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.